Cargando…

Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response

PURPOSE OF REVIEW: Gout is a systemic disease from which some patients develop numerous painful tophi that adversely affect quality of life and functionality. Some patients treated with oral urate-lowering therapy are unable to maintain serum urate levels below 6 mg/dL, and these patients, thus clas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Botson, John K., Baraf, Herbert S. B., Keenan, Robert T., Albert, John, Masri, Karim R., Peterson, Jeff, Yung, Christianne, Freyne, Brigid, Amin, Mona, Abdellatif, Abdul, Soloman, Nehad, Edwards, N. Lawrence, Strand, Vibeke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Crystal Arthritis (M Pillinger, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866281/ https://www.ncbi.nlm.nih.gov/pubmed/35167037 http://dx.doi.org/10.1007/s11926-022-01055-9

Ejemplares similares

Association Between Gout and All-Cause as well as Cardiovascular Mortality: A Systematic Review
por: Lottmann, Kathrin, et al.
Publicado: (2012)

Pegloticase in Uncontrolled Gout: The Infusion Nurse Perspective
por: Baxter, Britni, et al.
Publicado: (2023)

Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
por: Masri, Karim Richard, et al.
Publicado: (2022)

Tophus resolution with pegloticase: a prospective dual-energy CT study
por: Araujo, Elizabeth G, et al.
Publicado: (2015)

Pretreatment and Coadministration With Methotrexate Improved Durability of Pegloticase Response: An Observational, Proof-of-Concept Case Series
por: Botson, John K., et al.
Publicado: (2022)

Long-term safety of pegloticase in chronic gout refractory to conventional treatment
por: Becker, Michael A, et al.
Publicado: (2013)

Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial
por: Botson, John K., et al.
Publicado: (2022)

Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
por: Baraf, Herbert S. B., et al.
Publicado: (2014)

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
por: Botson, John K., et al.
Publicado: (2022)

Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study
por: Albert, John A., et al.
Publicado: (2020)

Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout
por: Broadwell, Aaron, et al.
Publicado: (2022)

Urate Handling in the Human Body
por: Hyndman, David, et al.
Publicado: (2016)

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings
por: Botson, John K., et al.
Publicado: (2023)

Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase
por: Keenan, Robert T., et al.
Publicado: (2019)

New advances in the treatment of gout: review of pegloticase
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Critical appraisal of the role of pegloticase in the management of gout
por: Ea, Hang-Korng, et al.
Publicado: (2012)

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout
por: Murdoch, Rachel, et al.
Publicado: (2021)

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

Gout and the risk of incident atrial fibrillation in older adults: a study of US Medicare data
por: Singh, Jasvinder A, et al.
Publicado: (2018)

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study
por: Hammer, Hilde Berner, et al.
Publicado: (2022)

Spontaneous resolution of acute gout: mechanisms and therapeutic targets
por: Shi, Meiling, et al.
Publicado: (2023)

Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective
por: Kapetanovic, Meliha C, et al.
Publicado: (2016)

Multiple common and rare variants of ABCG2 cause gout
por: Higashino, Toshihide, et al.
Publicado: (2017)

Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients
por: Nakayama, Akiyoshi, et al.
Publicado: (2020)

How Can We Improve Disease Education in People with Gout?
por: Fields, Theodore R., et al.
Publicado: (2018)

Impact of pegloticase on patient outcomes in refractory gout: current perspectives
por: Cunha, Rita N, et al.
Publicado: (2018)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

Occupational exposure to inorganic dust and risk of gout: a population-based study
por: Sigurdardottir, Valgerdur, et al.
Publicado: (2020)

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study
por: Botson, John K., et al.
Publicado: (2022)

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
por: te Kampe, Ritch, et al.
Publicado: (2022)

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
por: Baraf, Herbert SB, et al.
Publicado: (2013)

Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout
por: Kawamura, Yusuke, et al.
Publicado: (2019)

Factors influencing the kinetics of MSU crystal depletion measured with dual-energy CT in patients with gout
por: Laurent, Victor, et al.
Publicado: (2023)

A Case Report of Successful Management of Refractory Polyarticular Gout With Pegloticase
por: Alnabwani, Dina, et al.
Publicado: (2022)

Filling gaps in female gout: a cross-sectional study of comorbidities in 192 037 hospitalised patients
por: Rodríguez-Sosa, Enrique, et al.
Publicado: (2023)

Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease
por: Cipolletta, Edoardo, et al.
Publicado: (2023)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality
por: Pérez Ruiz, Fernando, et al.
Publicado: (2019)

Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care
por: Roddy, Edward, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_12b4ijgbkllthbmo7fr5cqi09v